Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Clinical Microbiology & Infectious Diseases
Published in: European Journal of Clinical Microbiology & Infectious Diseases 6/2016

01-06-2016 | Original Article

OPAT for cellulitis: its benefits and the factors that predispose to longer treatment

Authors: J. Zhang, E. Moore, R. Bousfield

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 6/2016

Login to get access

Abstract

This retrospective study investigated the demographics and treatment outcomes of patients with cellulitis receiving outpatient parenteral antibiotic therapy (OPAT) between 2010 and 2014 in Cambridge University Hospitals. The rate of treatment failure (as indicated by the readmission to hospital) was low, at 5.5%. Risk factors associated with a longer duration of OPAT treatment included: immunosuppression, peripheral vascular disease, obesity, lymphoedema, previous cellulitis and diabetes.
Literature
1.
Seaton R, Barr D (2013) Outpatient parenteral antibiotic therapy: principles and practice. Eur J Intern Med 24:617–623CrossRefPubMed
2.
Hitchcock J, Jepson A, Main J, Wickens H (2009) Establishment of an outpatient and home parenteral antimicrobial therapy service at a London teaching hospital: a case series. J Antimicrob Chemother 64(3):630–634CrossRefPubMed
3.
Figtree M, Konecny P, Jennings Z, Goh C, Krilis S, Miyakis S (2010) Risk stratification and outcome of cellulitis admitted to hospital. J Infect 60:431–439CrossRefPubMed
4.
Halilovic J, Heintz B, Brown J (2012) Risk factors for clinical failure in patients hospitalized with cellulitis and cutaneous abscess. J Infect 65:129–134CrossRef
5.
6.
Halpern K, Holder R, Langford N (2008) Ethnicity and other risk factors for acute lower limb cellulitis: a UK-based prospective case–control study. Br J Dermatol 158:1288–1292CrossRefPubMed
7.
Lillie P, Andrews D, Eaves K, Darton T, Chapman A (2010) Baseline factors predicting the duration of intravenous antibiotic therapy for cellulitis in an outpatient setting. Eur J Clin Microbiol Infect Dis 29:347–349CrossRefPubMed
Metadata
Title
OPAT for cellulitis: its benefits and the factors that predispose to longer treatment
Authors
J. Zhang
E. Moore
R. Bousfield
Publication date
01-06-2016
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 6/2016
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-016-2631-y

Other articles of this Issue 6/2016

European Journal of Clinical Microbiology & Infectious Diseases 6/2016 Go to the issue

Original Article

Aerobic culture of methanogenic archaea without an external source of hydrogen

Original Article

Serum concentrations of amoxicillin in neonates during continuous intravenous infusion

Original Article

Influenza A and B co-infection: a case–control study and review of the literature

Original Article

Early detection of Mycobacterium tuberculosis complex in BACTEC MGIT cultures using nucleic acid amplification

Original Article

Streptococcus suis in invasive human infections in Poland: clonality and determinants of virulence and antimicrobial resistance

Original Article

Medicinal leech therapy and Aeromonas spp. infection
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits